Cochlear (COH.AX) Aandeel Koers
Cochlear Koers
In de afgelopen 19 jaar liet Cochlear de omzet jaarlijks met 7,8% groeien tot 2,33 Miljard AUD. De winst per aandeel is de afgelopen 19 jaar met 1,2% per jaar gegroeid. Bij Cochlear is de nettowinstmarge met 6,3% ten opzichte van 17,6% enkele jaren geleden gedaald. Op de huidige koers komt het dividendrendement uit op ongeveer 4,57%. De uitkeringsratio ligt rond 95% van de winst. Het dividend is de afgelopen 19 jaar met 6,5% per jaar gegroeid. Het consensus-koersdoel voor Cochlear op 12 maanden bedraagt 252,40 AUD, circa 96,6% boven de huidige koers. Van de 19 analisten geven 8 het aandeel een koopadvies — per saldo een Houden-consensus.
Cochlear aandeelkoers
Cochlear bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Cochlear
Cochlear Ltd operates under a distinctive business model. As a global leader in the development and manufacturing of hearing solutions, the company primarily focuses on designing, producing, and marketing cochlear implant devices. Cochlear implants are electronic devices that provide a sense of sound to individuals with severe hearing loss or deafness. With a commitment to continuous innovation and superior quality, Cochlear Ltd offers a wide range of products and services that cater to the needs of patients, healthcare professionals, and hearing implant clinics worldwide. Through its robust business model, Cochlear Ltd aims to improve the lives of individuals with hearing challenges by providing cutting-edge and life-changing hearing solutions.
Cochlear Ltd is primarily active in the healthcare and medical device industries.
The main competitors of Cochlear Ltd in the market include major companies like Medtronic, Sonova Holding AG, and William Demant Holding A/S.
Cochlear Ltd is an Australian medical device company specializing in hearing implant solutions. Founded in 1981, it has a rich history and remarkable achievements in the field of implantable hearing devices. Cochlear is globally recognized for its groundbreaking advancements in the development and commercialization of cochlear implant technology. By providing solutions for people with profound hearing loss, Cochlear has improved the lives of millions worldwide. With a strong commitment to innovation and a dedicated team of experts, Cochlear remains at the forefront of the industry, continuously striving to enhance hearing experiences and transform lives through its state-of-the-art products and services.
Cochlear Ltd has achieved several significant milestones. One of the notable milestones includes the development and introduction of the world's first commercially successful cochlear implant in 1982. This breakthrough technology revolutionized the treatment of hearing loss for millions of people worldwide. Another key milestone for Cochlear Ltd was the successful launch of the Nucleus 6 Sound Processor, which offered enhanced hearing performance and wireless connectivity options. The company also made significant progress in expanding its global footprint, establishing subsidiaries and partnerships in different regions. Additionally, Cochlear Ltd received numerous industry recognitions and awards for its innovative products and contribution to the field of hearing healthcare.
Cochlear Ltd is primarily present in various countries and regions worldwide. The company operates in over 100 countries, including but not limited to Australia, the United States, Europe, Asia-Pacific, and Latin America. With its global presence, Cochlear Ltd has established itself as a leading provider of innovative hearing solutions and implantable hearing devices. Through its extensive network and collaborations, the company strives to enhance the lives of individuals with hearing loss across the world by providing advanced hearing technology and support.
Cochlear Ltd represents a strong set of values and corporate philosophy. The company is committed to improving the lives of people with hearing loss by providing innovative and reliable solutions. Cochlear believes in putting their customers first and delivering exceptional quality products and services. With a focus on continuous improvement, the company is dedicated to research and development to drive technological advancements in the field of hearing implants. Cochlear's corporate philosophy is centered around integrity, collaboration, and social responsibility. By embracing diversity and fostering a culture of inclusivity, Cochlear strives to make a positive impact on individuals and communities worldwide.
Analisten hanteren momenteel een gemiddeld koersdoel van 265,71 AUD voor het aandeel Cochlear (mediaan: 252,40 AUD), oftewel +107,0 % ten opzichte van de laatste koers. De consensus is gebaseerd op 19 analistenratings.
19 analisten beoordelen het aandeel Cochlear momenteel: 9 adviseren kopen, 9 houden en 1 verkopen.
Omgezet tegen de huidige wisselkoers noteert het aandeel Cochlear op 79,93 EUR (128,39 AUD).
Het aandeel Cochlear (COH.AX) is genoteerd aan 7 beurzen, waaronder: SIX (Zürich) (COH.SW), ASX (COH.AX), Frankfurt (OC5.F), München (OC5.MU), Düsseldorf (OC5.DU), Hamburg (OC5.HM).
Cochlear Ltd is a leading provider of innovative medical solutions for people with hearing loss. The company is headquartered in Sydney, Australia and operates in over 100 countries worldwide. Cochlear specializes in imitating the functionality of the human ear to provide a better hearing experience for those with hearing loss. They offer a wide range of products and services including cochlear implants, audioprocessors, cochlear replacement parts, and hearing aids. Cochlear implants are one of the company's main products, designed to help those with severe to profound hearing loss regain their ability to hear. The implant is an electronic device that bypasses the inner ear by sending signals directly to the auditory nerve. In addition to cochlear implants and audioprocessors, Cochlear also offers wireless accessory devices such as TV streamers to enhance the listening experience. They have a dedicated department for manufacturing hearing aids called "Cochlear Devices," which are designed for individuals with mild to moderate hearing loss. The company is always working on new technologies to improve the listening experience for individuals with hearing loss, including their latest innovation, the Cochlear sound processor, which utilizes artificial intelligence to automatically adapt to different environments for optimal sound quality. Cochlear provides a range of services to support their customers, including training and support for healthcare professionals who implant or adjust Cochlear devices. They collaborate with customers, clinics, research institutions, and universities to develop the latest advancements in technology to improve the lives of individuals with hearing loss. Cochlear's business model is focused on promoting health and well-being, providing innovative hearing device and implant technologies, and comprehensive services to ensure an excellent patient experience. They are committed to playing a leading role in the treatment of hearing loss and helping people worldwide overcome their hearing challenges.
De omzet van Cochlear bedraagt 2,33 Miljard AUD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De winst van Cochlear bedraagt 147,30 Miljoen AUD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Cochlear bedraagt momenteel 57,00. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Cochlear-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Cochlear bedraagt momenteel 3,60. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Cochlear-aandeel.
De Eulerpool Kwaliteitsscore voor Cochlear is 4/10.
De ISIN van Cochlear is AU000000COH5. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Cochlear is 898321. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Cochlear is COH.AX. Onder dit beurstickersymbool wordt het Cochlear-aandeel op de beurs verhandeld.
Cochlear aandeel
Cochlear Peer Group
Cochlear Ticker
Cochlear FIGI
Alle fundamentals en diepgaande analyse van Cochlear
Onze aandelenanalyse van het Cochlear-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Cochlear. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: